A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healthy adults

2023-505026-34-00 Protocol NN6022-7683 Human pharmacology (Phase I) - First administration to humans Ended

Start 26 Mar 2024 · End 17 Feb 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol NN6022-7683

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 56
Countries 1
Sites 1

Cardiometabolic diseases

Key facts

Sponsor
Novo Nordisk A/S
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Male Urogenital Diseases [C12], Diseases [C] - Cardiovascular Diseases [C14], Diseases [C] - Digestive System Diseases [C06]
Trial duration
26 Mar 2024 → 17 Feb 2025
Decision date (initial)
2024-03-11
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-505026-34-00
WHO UTN
U1111-1290-1002

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Cardiometabolic diseases

VersionLevelCodeTermSystem organ class
23.0 LLT 10082306 Cardiometabolic syndrome 10027433

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Novo Nordisk A/S

Sponsor organisation
Novo Nordisk A/S
Address
Novo Alle 1
City
Bagsvaerd
Postcode
2880
Country
Denmark

Scientific contact point

Organisation
Novo Nordisk A/S
Contact name
EU Submission Hub

Public contact point

Organisation
Novo Nordisk A/S
Contact name
EU Submission Hub

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 56 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-03-26 2025-02-17 2024-03-28 2025-02-17

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-01-22 Netherlands Acceptable
2024-03-11
2024-03-11
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-03-13 Netherlands Acceptable
2024-03-11
2024-03-13
3 SUBSTANTIAL MODIFICATION SM-1 2024-07-05 Netherlands Acceptable
2024-07-11
2024-07-11
4 SUBSTANTIAL MODIFICATION SM-2 2024-09-26 Netherlands Acceptable
2024-10-14
2024-10-14
5 NON SUBSTANTIAL MODIFICATION NSM-2 2024-12-03 Netherlands Acceptable
2024-10-14
2024-12-03
6 SUBSTANTIAL MODIFICATION SM-3 2025-07-03 Netherlands Acceptable
2025-07-04
2025-07-09